ClinicalTrials.gg
CompletedNCT03253796Updated Jul 28, 2023Results posted

Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

A Phase 4 interventional study of Golimumab and Placebo in Spondyloarthritis, sponsored by Merck Sharp & Dohme LLC. Completed at 71 sites in 9 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of treatment withdrawal compared to continued treatment with golimumab (GLM) administered by subcutaneous (SC) injection on the incidence of a "flare" in non-radiographic axial spondyloarthritis over up to 12 months. The primary hypothesis is that continued treatment with golimumab is superior to treatment withdrawal, based on the percentage of subjects without a "flare" during up to 12 months of blinded therapy.

02

Conditions studied

  • Spondyloarthritis

Browse trials for

03

In context

Spondylarthritis

203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.

This study's enrollment of 323 is above the median of 108 across 106 interventional studies indexed under Spondylarthritis.

Browse Spondylarthritis studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is not of , or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication
  • Has chronic back pain of ≥3 months duration by history
  • Has physician-diagnosed active non-radiographic axial spondyloarthritis (nr-axSpA) with disease duration \<= 5 years
  • Meets one of the following criteria:

    1. Has active inflammation on magnetic resonance imaging (MRI) highly suggestive of sacroiliitis associated with spondyloarthropathy and 1 or more of the following spondyloarthritis (SpA) characteristics:

      • Inflammatory back pain
      • Arthritis (physician-diagnosed)
      • Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)
      • Dactylitis (physician-diagnosed)
      • Psoriasis (physician-diagnosed)
      • History of physician-diagnosed inflammatory bowel disease (IBD)
      • History of uveitis confirmed by an ophthalmologist
      • Good response to nonsteroidal anti-inflammatory drugs (NSAID)
      • Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)
      • Elevated C-reactive protein (CRP)

        • Human leukocyte antigen B27 (HLA-B27)+ gene OR
    2. Has a HLA-B27+ gene and 2 or more of the following SpA characteristics:

      • Inflammatory back pain
      • Arthritis (physician-diagnosed)
      • Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)
      • Dactylitis (physician-diagnosed)
      • Psoriasis (physician-diagnosed)
      • History of physician-diagnosed inflammatory bowel disease (IBD)
      • History of uveitis confirmed by an ophthalmologist
      • Good response to nonsteroidal anti-inflammatory drugs (NSAID)
      • Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)
      • Elevated C-reactive protein (CRP)
  • Has elevated CRP at Screening or evidence of active inflammation in the sacroiliac joints on MRI
  • Has an Ankylosing Spondylitis Disease Activity Score (ASDAS) >= 2.1 at Screening
  • Shows high disease activity at Screening and Baseline of both a Total Back Pain score of ≥4 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of >= 4
  • Has an acceptable history of NSAID use
  • Has no history of untreated latent or active tuberculosis (TB) prior to Screening
  • Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB
  • Agrees to undergo screening for virus (HBV) and demonstrates negative results for hepatitis B surface antigen (HBsAg) and HBV deoxyribonucleic acid (DNA)

Exclusion criteria

Exclusion Criteria:

  • Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4 on conventional x-rays
  • Is a nursing or pregnant female, or intends to become pregnant within 6 months after receiving trial medication
  • Intends to donate eggs (female participants) or sperm (male participants) while receiving trial medication or within 6 months after trial medication
  • Has any condition or situation that would interfere with the trial evaluations or participation in the trial
  • Has ever received any cytotoxic drugs, including chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents
  • Has received any treatment listed below more recently than the indicated off-drug period prior to Screening

      • Disease-modifying anti-rheumatic drugs (30 days off drug)
      • (3 months off drug)
      • medications (30 days or 5 half-lives off drug, whichever is longer)
      • Bacille Calmette-Guerin (BCG) vaccination (12 months off drug)
  • Has any systemic inflammatory condition, including psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD
  • Has a history of latent or active granulomatous infection prior to Screening
  • Had a nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to Screening
  • Has a history of an infected joint prosthesis, or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced
  • Had a serious infection, has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to Baseline
  • Had a history of, or ongoing, chronic or recurrent infectious disease
  • Is known to be infected with (HIV) or seropositive for virus (HCV)
  • Has had a chest x-ray within 2 months prior to Screening that shows an abnormality suggestive of a current active infection or
  • Has a history of lymphoproliferative disease
  • Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured)
  • Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis
  • Has a history of or concurrent congestive heart failure of any grade
  • Has a transplanted organ (with the exception of a corneal transplant performed >= 3 months prior to baseline)
  • Has current signs or symptoms of significant medical illness which could interfere with the trial, or require treatment that might interfere with the trial
  • Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    GLM SC QM (Full Treatment Regimen)

    Period 1: participants are treated with open-label (OL) GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded SC GLM QM for up to 12 months

    Biological: Golimumab

  • Experimental
    GLM SC Q2M (Reduced Treatment Regimen)

    Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded GLM SC every other month alternating with matching placebo to GLM every other month for up to 12 months

    Biological: Golimumab · Biological: Placebo

  • Placebo comparator
    Placebo (Treatment Withdrawal Regimen)

    Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded placebo for up to 12 months

    Biological: Golimumab · Biological: Placebo

  • Experimental
    OL GLM Retreatment

    Participants who experience a disease flare during double-blinded treatment in Period 2 will discontinue blinded treatment and receive OL GLM SC QM.

    Biological: Golimumab

Interventions

  • BiologicalGolimumab

    Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.

    Also known as: MK-8259, Simponi®

  • BiologicalPlacebo

    Injections of matching placebo for golimumab.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Without a Disease Activity Flare During Period 2

    Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

Secondary outcomes

  1. Percentage of Participants With a Flare Who Show a Clinical Response Within 3 Months of Open-Label Golimumab Retreatment

    Clinical response is defined as Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score improvement of ≥2.0 or ≥50% improvement within 3 months of the start of retreatment, relative to the mean of the two consecutive BASDAI scores that defined the flare. Sustained clinical response refers to participants who attained clinical response and maintained BASDAI criteria throughout the 3-month retreatment period. Response data was collected throughout Period 2 (12 months) and censored to include only the first 3 months after retreatment for a disease flare. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.

    Time frame: Up to 3 months following start of retreatment

  2. Time to First Disease Flare

    The Kaplan-Meier analysis of time to first "flare" in Period 2 is represented by the percentage of participants who experienced a disease flare relative to baseline prior to the first dose of double-blind treatment in Period 2. Disease flare is defined as ASDAS at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1.

    Time frame: Month 3, Month 6, Month 9, and Month 12

  3. Percentage of Participants Achieving ASAS20 (Assessment in SpondyloArthritis International Society) Response (Double-blind Treatment)

    ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Up to 12 months

  4. Percentage of Participants Achieving ASAS20 Response (Open-label Retreatment)

    ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Up to 12 months

  5. Percentage of Participants Achieving ASAS40 Response (Double-blind Treatment)

    ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Up to 12 months

  6. Percentage of Participants Achieving ASAS40 Response (Open-label Retreatment)

    ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Up to 12 months

  7. Percentage of Participants Achieving ASAS Partial Remission (Double-blind Treatment)

    ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Up to 12 months

  8. Percentage of Participants Achieving ASAS Partial Remission (Open-label Retreatment)

    ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

    Time frame: Up to 12 months

  9. Percentage of Participants Achieving BASDAI50 Response (Double-blind Treatment)

    BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of double-blind treatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

  10. Percentage of Participants Achieving BASDAI50 Response (Open-label Retreatment)

    BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of open-label retreatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

  11. Percentage of Participants Achieving Inactive Disease Status (Double-Blind Treatment)

    Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

  12. Percentage of Participants Achieving Inactive Disease Status (Open-label Retreatment)

    Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

  13. Percentage of Participants Who Experienced an Adverse Event (AE) in Period 2

    This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE. The analysis includes AEs that occurred through 90 days after the last dose of study treatment.

    Time frame: Up to approximately 15 months

  14. Percentage of Participants Who Discontinued Study Treatment Due to an AE in Period 2

    This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE.

    Time frame: Up to approximately 12 months

Other outcomes

  1. Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Withdrawal Regimens)

    Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

  2. Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Reduced Treatment Regimen)

    Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

    Time frame: Up to 12 months

07

Results

Posted May 4, 2022

Participant flow

Period 1: Run-In
Participant flow — Period 1: Run-In
MilestoneOpen-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
Started3230000
Completed2070000
Not completed1160000
Withdrew: Adverse event40000
Withdrew: Lack of efficacy10000
Withdrew: Lack of qualifying event980000
Withdrew: Protocol violation50000
Withdrew: Withdrawal by subject80000
Period 2: Withdrawal vs Continued Tx
Participant flow — Period 2: Withdrawal vs Continued Tx
MilestoneOpen-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
Started06364620
Completed05343210
Not completed01021410
Withdrew: Adverse event00200
Withdrew: Physician decision00100
Withdrew: Withdrawal by subject00230
Withdrew: Did not attain inactive disease in period 100100
Withdrew: Disease flare, transitioned to open-label retreatment01015380
Period 2: Open-Label Retreatment
Participant flow — Period 2: Open-Label Retreatment
MilestoneOpen-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
Started000063
Completed000058
Not completed00005
Withdrew: Withdrawal by subject00005

Outcome measures

PrimaryPercentage of Participants Without a Disease Activity Flare During Period 2

Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Without a Disease Activity Flare During Period 2
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Percentage of Participants Without a Disease Activity Flare During Period 284.168.333.9
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Miettinen and Nurminen · p = <0.001 · Difference in percentage: 50.2 · 95% CI 34.1 to 63.6Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
  • Golimumab Q2M (Reduced Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Meittinen and Nurminen · p = <0.001 · Difference in percentage: 34.4 · 95% CI 17.0 to 49.7Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
SecondaryPercentage of Participants With a Flare Who Show a Clinical Response Within 3 Months of Open-Label Golimumab Retreatment

Clinical response is defined as Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score improvement of ≥2.0 or ≥50% improvement within 3 months of the start of retreatment, relative to the mean of the two consecutive BASDAI scores that defined the flare. Sustained clinical response refers to participants who attained clinical response and maintained BASDAI criteria throughout the 3-month retreatment period. Response data was collected throughout Period 2 (12 months) and censored to include only the first 3 months after retreatment for a disease flare. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.

Time frame:
Up to 3 months following start of retreatment
Reported as:
Number · Percentage of participants
Percentage of Participants With a Flare Who Show a Clinical Response Within 3 Months of Open-Label Golimumab Retreatment
Percentage of participantsOpen-Label Retreatment
Within 1 month of retreatment90.6 (79.3 to 96.9)
Within 2 months of retreatment96.2 (87.0 to 99.5)
Within 3 months of retreatment96.2 (87.0 to 99.5)
Sustained clinical response71.7 (57.7 to 83.2)
SecondaryTime to First Disease Flare

The Kaplan-Meier analysis of time to first "flare" in Period 2 is represented by the percentage of participants who experienced a disease flare relative to baseline prior to the first dose of double-blind treatment in Period 2. Disease flare is defined as ASDAS at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1.

Time frame:
Month 3, Month 6, Month 9, and Month 12
Reported as:
Number · Percentage of participants
Time to First Disease Flare
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Month 314.37.941.9
Month 614.317.558.1
Month 914.320.661.3
Month 1215.923.861.3
SecondaryPercentage of Participants Achieving ASAS20 (Assessment in SpondyloArthritis International Society) Response (Double-blind Treatment)

ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS20 (Assessment in SpondyloArthritis International Society) Response (Double-blind Treatment)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Percentage of Participants Achieving ASAS20 (Assessment in SpondyloArthritis International Society) Response (Double-blind Treatment)9.53.20.0
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 9.5 · 95% CI 3.3 to 19.4Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
  • Golimumab Q2M (Reduced Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 3.2 · 95% CI -2.8 to 10.9Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
SecondaryPercentage of Participants Achieving ASAS20 Response (Open-label Retreatment)

ASAS20 is a 20% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥20% from Baseline and an absolute improvement from Baseline of ≥1.0 in at least 3 of 4 domains, and 2) Absence of deterioration from Baseline (defined as a ≥20% worsening and an absolute worsening of ≥1.0) in the potential remaining domain. Baseline for ASAS20 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS20 Response (Open-label Retreatment)
Percentage of participantsOpen-Label Retreatment
Percentage of Participants Achieving ASAS20 Response (Open-label Retreatment)94.3 (84.3 to 98.8)
SecondaryPercentage of Participants Achieving ASAS40 Response (Double-blind Treatment)

ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS40 Response (Double-blind Treatment)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Percentage of Participants Achieving ASAS40 Response (Double-blind Treatment)000
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 0.0 · 95% CI -5.9 to 5.8Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
  • Golimumab Q2M (Reduced Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 0.0 · 95% CI -5.9 to 5.8Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
SecondaryPercentage of Participants Achieving ASAS40 Response (Open-label Retreatment)

ASAS40 is a 40% improvement in response (per the Assessment in Ankylosing Spondylitis International Working Group) defined as meeting 2 criteria: 1) An improvement of ≥40% from Baseline and an absolute improvement from Baseline of ≥2.0 in at least 3 of 4 domains, and 2) No deterioration from Baseline in the potential remaining domain. Baseline for ASAS40 analysis is defined as the last ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: the Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS40 Response (Open-label Retreatment)
Percentage of participantsOpen-Label Retreatment
Percentage of Participants Achieving ASAS40 Response (Open-label Retreatment)90.6 (79.3 to 96.9)
SecondaryPercentage of Participants Achieving ASAS Partial Remission (Double-blind Treatment)

ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of double-blind treatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS Partial Remission (Double-blind Treatment)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Percentage of Participants Achieving ASAS Partial Remission (Double-blind Treatment)85.785.771.0
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 14.7 · 95% CI 0.2 to 29.0Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
  • Golimumab Q2M (Reduced Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 14.7 · 95% CI 0.2 to 29.1Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
SecondaryPercentage of Participants Achieving ASAS Partial Remission (Open-label Retreatment)

ASAS partial remission is defined as a score of ≤2 in all 4 ASAS domains. Baseline for this analysis is defined as the ASAS score prior to the first dose of open-label retreatment in Period 2. The ASAS consists of 4 domains: Patient Global Disease Assessment (PGDn), total back pain, function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and morning stiffness (mean of questions 5 and 6 of Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Each domain is measured on a 10-point numeric scale from 0=no disease symptoms/impact to 10=extreme disease symptoms/impact, with a higher score indicating more severe impairment.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS Partial Remission (Open-label Retreatment)
Percentage of participantsOpen-Label Retreatment
Percentage of Participants Achieving ASAS Partial Remission (Open-label Retreatment)92.5 (81.8 to 97.9)
SecondaryPercentage of Participants Achieving BASDAI50 Response (Double-blind Treatment)

BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of double-blind treatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving BASDAI50 Response (Double-blind Treatment)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Percentage of Participants Achieving BASDAI50 Response (Double-blind Treatment)49.230.224.2
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 24.9 · 95% CI 8.5 to 40.3Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
  • Golimumab Q2M (Reduced Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 5.9 · 95% CI -9.9 to 21.3Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
SecondaryPercentage of Participants Achieving BASDAI50 Response (Open-label Retreatment)

BASDAI50 is defined as ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Assessment Index (BASDAI) score. Baseline for BASDAI50 analysis is defined as the last BASDAI score prior to the first dose of open-label retreatment in Period 2. The BASDAI is a summary of 6 participant-assessed measures rated on scales of 0 (none) to 10 (very severe): fatigue, spinal pain, joint pain/swelling, tenderness, morning stiffness, and duration of morning stiffness \[0 (zero) to 10 (2 or more hours)\]. The BASDAI score is the mean of responses to the 6 questions with a minimum of 0 and a maximum of 10. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving BASDAI50 Response (Open-label Retreatment)
Percentage of participantsOpen-Label Retreatment
Percentage of Participants Achieving BASDAI50 Response (Open-label Retreatment)98.1 (89.9 to 100.0)
SecondaryPercentage of Participants Achieving Inactive Disease Status (Double-Blind Treatment)

Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Inactive Disease Status (Double-Blind Treatment)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)
Percentage of Participants Achieving Inactive Disease Status (Double-Blind Treatment)85.784.161.3
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 24.4 · 95% CI 9.1 to 39.0Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
  • Golimumab Q2M (Reduced Treatment Regimen) vs Placebo (Treatment Withdrawal Regimen) · Difference in percentage: 22.8 · 95% CI 7.3 to 37.7Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
SecondaryPercentage of Participants Achieving Inactive Disease Status (Open-label Retreatment)

Inactive disease status is defined as an ASDAS score \<1.3. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Inactive Disease Status (Open-label Retreatment)
Percentage of participantsOpen-Label Retreatment
Percentage of Participants Achieving Inactive Disease Status (Open-label Retreatment)90.6 (79.3 to 96.9)
SecondaryPercentage of Participants Who Experienced an Adverse Event (AE) in Period 2

This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE. The analysis includes AEs that occurred through 90 days after the last dose of study treatment.

Time frame:
Up to approximately 15 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE) in Period 2
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
Percentage of Participants Who Experienced an Adverse Event (AE) in Period 246.046.932.341.3
SecondaryPercentage of Participants Who Discontinued Study Treatment Due to an AE in Period 2

This endpoint evaluated the safety and tolerability of withdrawing from or continuing treatment with golimumab in Period 2. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE.

Time frame:
Up to approximately 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE in Period 2
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
Percentage of Participants Who Discontinued Study Treatment Due to an AE in Period 20.04.71.60.0
Other pre-specifiedPercentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Withdrawal Regimens)

Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Withdrawal Regimens)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M and Placebo (Withdrawal Regimens)
Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Withdrawal Regimens)84.151.2
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Golimumab Q2M and Placebo (Withdrawal Regimens) · Miettinen and Nurminen · p = <0.001 · Difference in percentage: 32.9 · 95% CI 19.2 to 44.5Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor
Other pre-specifiedPercentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Reduced Treatment Regimen)

Disease flare is defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) at two consecutive visits that both show either absolute score ≥2.1 or a post-withdrawal increase of ≥1.1 relative to baseline prior to the first dose of double-blind treatment in Period 2. The ASDAS is a composite index assessing disease activity in axial spondyloarthropathies that consists of 4 self-assessed parameters and 1 laboratory parameter. The self-assessed parameters of back pain, duration of morning stiffness, Patient Global Disease Assessment (PGDn), and peripheral pain/swelling are individually scored on a numeric scale of 0 to 10, with 0 being low activity/impact and 10 being high activity/impact. The self-assessed criteria and the laboratory value of CRP are combined to provide the total ASDAS score, which has a lower limit of 0.6 and no defined upper limit. A higher score indicates greater disease activity.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Reduced Treatment Regimen)
Percentage of participantsGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)
Percentage of Participants Without a Disease Activity Flare During Period 2 (Full Treatment Regimen Versus Reduced Treatment Regimen)84.168.3
Statistical analysis
  • Golimumab QM (Full Treatment Regimen) vs Golimumab Q2M (Reduced Treatment Regimen) · Miettinen and Nurminen · p = 0.037 · Difference in percentage: 15.9 · 95% CI 0.9 to 30.5Derived based on the stratified Miettinen and Nurminen method with CRP level (\>6 mg/L or ≤ 6 mg/L) as a stratification factor

Adverse events

Collected over Up to 10 months in Period 1 (Open-Label Run-in) and up to 15 months in Period 2 (Withdrawal vs Continued Treatment) for a total of up to 25 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label Run-In Golimumab QM0/323 (0%)7/323 (2.2%)79/323 (24.5%)
Golimumab QM (Full Treatment Regimen)0/63 (0%)1/63 (1.6%)13/63 (20.6%)
Golimumab Q2M (Reduced Treatment Regimen)0/64 (0%)1/64 (1.6%)17/64 (26.6%)
Placebo (Treatment Withdrawal Regimen)0/62 (0%)1/62 (1.6%)11/62 (17.7%)
Open-Label Retreatment0/63 (0%)0/63 (0%)11/63 (17.5%)
Most frequent serious events
Most frequent serious events
EventOpen-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
Meniscus injuryInjury, poisoning and procedural complications0/3230/630/641/620/63
Joint injuryInjury, poisoning and procedural complications0/3231/630/640/620/63
Pyelonephritis acuteInfections and infestations0/3230/631/640/620/63
Renal colicRenal and urinary disorders1/3230/631/640/620/63
Cholecystitis chronicHepatobiliary disorders1/3230/630/640/620/63
Pilonidal cystInfections and infestations1/3230/630/640/620/63
Sinusitis bacterialInfections and infestations1/3230/630/640/620/63
ArthritisMusculoskeletal and connective tissue disorders1/3230/630/640/620/63
ExostosisMusculoskeletal and connective tissue disorders1/3230/630/640/620/63
Joint instabilityMusculoskeletal and connective tissue disorders1/3230/630/640/620/63
Most frequent other events
Most frequent other events
EventOpen-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label Retreatment
NasopharyngitisInfections and infestations36/3236/636/643/624/63
PharyngitisInfections and infestations12/3232/636/643/621/63
Upper respiratory tract infectionInfections and infestations16/3232/633/642/625/63
HeadacheNervous system disorders24/3234/632/644/621/63

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Open-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label RetreatmentTotal
Period 1: Open-Label Run-In32.5 ± 7.2————32.5 ± 7.2
Period 2: Withdrawal vs Continued Tx—31.4 ± 8.030.8 ± 6.732.9 ± 6.8—31.7 ± 7.2
Period 2: Open-Label Retreatment————33.4 ± 6.733.4 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Open-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label RetreatmentTotal
Period 1: Open-Label Run-In — Female109————109
Period 1: Open-Label Run-In — Male214————214
Period 2: Withdrawal vs Continued Tx — Female—192116—56
Period 2: Withdrawal vs Continued Tx — Male—444346—133
Period 2: Open-Label Retreatment — Female————2020
Period 2: Open-Label Retreatment — Male————4343
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label RetreatmentTotal
Period 1: Open-Label Run-In — Hispanic or Latino2————2
Period 1: Open-Label Run-In — Not Hispanic or Latino321————321
Period 1: Open-Label Run-In — Unknown or Not Reported0————0
Period 2: Withdrawal vs Continued Tx — Hispanic or Latino—000—0
Period 2: Withdrawal vs Continued Tx — Not Hispanic or Latino—636462—189
Period 2: Withdrawal vs Continued Tx — Unknown or Not Reported—000—0
Period 2: Open-Label Retreatment — Hispanic or Latino————00
Period 2: Open-Label Retreatment — Not Hispanic or Latino————6363
Period 2: Open-Label Retreatment — Unknown or Not Reported————00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label RetreatmentTotal
Period 1: Open-Label Run-In — American Indian or Alaska Native000000
Period 1: Open-Label Run-In — Asian0————0
Period 1: Open-Label Run-In — Native Hawaiian or Other Pacific Islander0————0
Period 1: Open-Label Run-In — Black or African American0————0
Period 1: Open-Label Run-In — White323————323
Period 1: Open-Label Run-In — More than one race0————0
Period 1: Open-Label Run-In — Unknown or Not Reported0————0
Period 2: Withdrawal vs Continued Tx — American Indian or Alaska Native—000—0
Period 2: Withdrawal vs Continued Tx — Asian—000—0
Period 2: Withdrawal vs Continued Tx — Native Hawaiian or Other Pacific Islander—000—0
Period 2: Withdrawal vs Continued Tx — Black or African American—000—0
Period 2: Withdrawal vs Continued Tx — White—636462—189
Period 2: Withdrawal vs Continued Tx — More than one race—000—0
Period 2: Withdrawal vs Continued Tx — Unknown or Not Reported—000—0
Period 2: Open-Label Retreatment — American Indian or Alaska Native————00
Period 2: Open-Label Retreatment — Asian————00
Period 2: Open-Label Retreatment — Native Hawaiian or Other Pacific Islander————00
Period 2: Open-Label Retreatment — Black or African American————00
Period 2: Open-Label Retreatment — White————6363
Period 2: Open-Label Retreatment — More than one race————00
Period 2: Open-Label Retreatment — Unknown or Not Reported————00
C-Reactive Protein (CRP) Category at Enrollment
C-Reactive Protein (CRP) Category at Enrollment(Participants)Open-Label Run-In Golimumab QMGolimumab QM (Full Treatment Regimen)Golimumab Q2M (Reduced Treatment Regimen)Placebo (Treatment Withdrawal Regimen)Open-Label RetreatmentTotal
Period 1: Open-Label Run-In — > 6 mg/L196————196
Period 1: Open-Label Run-In — ≤ 6 mg/L127————127
Period 2: Withdrawal vs Continued Tx — > 6 mg/L—404039—119
Period 2: Withdrawal vs Continued Tx — ≤ 6 mg/L—232423—70
Period 2: Open-Label Retreatment — > 6 mg/L————3838
Period 2: Open-Label Retreatment — ≤ 6 mg/L————2525
08

Study locations

71 sites
  • FN Brno ( Site 0005)
    Brno, 625 00, Czechia
  • Revmatologie s.r.o. ( Site 0009)
    Brno, 638 00, Czechia
  • Artroscan s.r.o. ( Site 0007)
    Ostrava-Trebovice, 722 00, Czechia
  • CCBR Ostrava s.r.o. ( Site 0001)
    Ostrava, 702 00, Czechia
  • CCR Czech a.s. ( Site 0003)
    Pardubice, 530 02, Czechia
  • CCR Prague s.r.o ( Site 0004)
    Praha, 130 00, Czechia
  • Fakultni nemocnice v Motole ( Site 0127)
    Praha, 150 06, Czechia
  • Medical Plus s.r.o ( Site 0010)
    Uherske Hradiste, 686 01, Czechia
  • PV - Medical s.r.o. ( Site 0006)
    Zlin, 760 01, Czechia
  • Universitaetsklinik der Charite Berlin ( Site 0023)
    Berlin, 12203, Germany
  • Rheumazentrum Ruhrgebiet ( Site 0021)
    Herne, 44649, Germany
  • U. klinikum Koeln AOER ( Site 0025)
    Koeln, 50937, Germany
  • Klinikum der Universitaet Muenchen - LMU ( Site 0026)
    Muenchen, 80336, Germany
  • Herbert Kellner Innere Medizin Rheumatologie und Gastroenterologie ( Site 0022)
    Muenchen, 80639, Germany
  • Antonius Ziekenhuis Sneek ( Site 0043)
    Sneek, Friesland 8601 ZK, Netherlands
  • Vrij Universiteit Medisch Centrum ( Site 0044)
    Amsterdam, 1081 HV, Netherlands
  • Leids Universitair Medisch Centrum ( Site 0041)
    Leiden, 2333 ZA, Netherlands
  • Maasstad Ziekenhuis ( Site 0042)
    Rotterdam, 3079 DZ, Netherlands
  • Centrum Medyczne Pratia Katowice ( Site 0059)
    Katowice, Slaskie 40-081, Poland
  • Prywatna Praktyka Lekarska, Dr. med. Pawel Hrycaj ( Site 0060)
    Poznan, Wielkopolskie 61-397, Poland
  • NZOZ Osteo-Medic s.c. A. Racewicz, R. Supronik ( Site 0058)
    Bialystok, 15-351, Poland
  • Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej ( Site 0153)
    Bydgoszcz, 85-168, Poland
  • Centrum Kliniczno-Badawcze ( Site 0152)
    Elblag, 82-300, Poland
  • Krakow Medical Centre ( Site 0052)
    Krakow, 31-501, Poland
  • NZOZ Reumed ( Site 0051)
    Lublin, 20-582, Poland
  • Pomorskie Cent. Reumatologiczne IM.Dr. Titz-Kosko W Sopocie Sp. Z.o.o. ( Site 0057)
    Sopot, 81-759, Poland
  • Lubelskie Centrum Diagnostyczne ( Site 0053)
    Swidnik, 21-040, Poland
  • NZOZ Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych ( Site 0151)
    Torun, 87-100, Poland
  • Reumatika ( Site 0055)
    Warszawa, 02-691, Poland
  • Centrul Medical de Diagnostic si Tratament Ambulator Neomed ( Site 0177)
    Brasov, 500283, Romania
  • Clinical Hospital Ioan Cantacuzino ( Site 0184)
    Bucaresti, 020475, Romania
  • Colentina Clinical Hospital ( Site 0231)
    Bucarest, 020125, Romania
  • Spitalul Clinic Sfanta Maria ( Site 0182)
    Bucharest, 011172, Romania
  • SC Duo Medical SRL ( Site 0183)
    Bucuresti, 010584, Romania
  • Spitalul Clinic Judetean de Urgenta Cluj-Napoca ( Site 0176)
    Cluj Napoca, 400006, Romania
  • RKMed Center ( Site 0180)
    Iasi, 700127, Romania
  • S.C.Pelican Impex S.R.L ( Site 0232)
    Oradea, 410450, Romania
  • Covamed Serv SRL ( Site 0178)
    Sfantu Gheorghe, 520052, Romania
  • Cabinet Medical Medicina Interna Dr. Triff Carina ( Site 0179)
    Timisoara, 300766, Romania
  • GUZ Regional Clinical Hospital ( Site 0076)
    Saratov, Oktyabrskiy Region 410053, Russian Federation
  • Rheumatology Research Institute n.a. V.A.Nasonova of RAMS ( Site 0061)
    Moscow, 115522, Russian Federation
  • SPb SBHI Clinical Rheumatological Hospital 25 ( Site 0077)
    Saint Petersburg, 190068, Russian Federation
  • SBHI Leningrad Regional Clinical Hospital ( Site 0065)
    Saint Petersburg, 194291, Russian Federation
  • LLC Sanavita ( Site 0074)
    Saint-Petersburg, 195257, Russian Federation
  • Tolyatti City Clinical Hospital 5 ( Site 0069)
    Tolyatti, 445039, Russian Federation
  • Yaroslavl Clinical Hospital for Emergency Care na. NV. Solovyev. ( Site 0075)
    Yaroslavl, 150003, Russian Federation
  • Hospital de Basurto ( Site 0082)
    Bilbao, 48013, Spain
  • Hospital Universitario Reina Sofia ( Site 0081)
    Cordoba, 14004, Spain
  • Hospital Universitario La Paz ( Site 0083)
    Madrid, 28046, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca ( Site 0085)
    Murcia, 30120, Spain
  • Akdeniz Universitesi Tip Fakultesi Romatoloji Departmani ( Site 0094)
    Antalya, Ankara 07070, Turkey
  • Ankara Numune Egitim Arastirma Hastanesi ( Site 0092)
    Ankara, 06100, Turkey
  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0091)
    Ankara, 06100, Turkey
  • Ankara Universitesi Tıp Fakultesi ( Site 0093)
    Ankara, 06230, Turkey
  • Pamukkale Unv. Tip Fak. ( Site 0097)
    Denizli, 20070, Turkey
  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0098)
    Istanbul, 34899, Turkey
  • Kocaeli Universitesi Tip Fakultesi Ic Hastaliklari ( Site 0096)
    Kocaeli, 41380, Turkey
  • Cherkassy Regional hospital of Cherkassy Regional council ( Site 0221)
    Cherkassy, 18009, Ukraine
  • MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0222)
    Dnipropetrovsk, 49005, Ukraine
  • SI National Institute of therapy n.a L.T. Maloi NAMS of Ukraine ( Site 0261)
    Kharkiv, 61039, Ukraine
  • ME of Health Care Kharkiv City Clinical Hospital #8 ( Site 0262)
    Kharkiv, 61176, Ukraine
  • Kyivska miska klinichna likarnia N3 ( Site 0266)
    Kyiv, 02125, Ukraine
  • M. D. Strazhesko Institute of Cardiology. ( Site 0264)
    Kyiv, 03680, Ukraine
  • Medical Center Ibn Sina ( Site 0268)
    Kyiv, 04050, Ukraine
  • Clinic of Modern Rheumatology ( Site 0265)
    Kyiv, 04070, Ukraine
  • Communal City Clinical Hospital #4 ( Site 0230)
    Lviv, 79011, Ukraine
  • MI Odesa Regional Clinical Hospital ( Site 0226)
    Odesa, 65117, Ukraine
  • M.V.Sklifosovskyi Poltava Regional Clinical Hospital ( Site 0224)
    Poltava, 36011, Ukraine
  • Vinnitsa Regional Clinical Hospital n.a. Pirogov ( Site 0225)
    Vinnutsya, 21018, Ukraine
  • SRI of Invalid Rehabilitation of Vinnytsia M.I.Pyrogov ( Site 0263)
    Vinnytsia, 21000, Ukraine
  • Zaporizhzha Regional Clinical Hospital ( Site 0223)
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Publications

  • Weinstein CLJ, Sliwinska-Stanczyk P, Hala T, Stanislav M, Tzontcheva A, Yao R, Berd Y, Curtis SP, Philip G. Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK). Rheumatology (Oxford). 2023 Nov 2;62(11):3601-3609. doi: 10.1093/rheumatology/kead112. PubMed 36919768 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2021, 40 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2017
First posted
Aug 18, 2017
StartActual
Nov 7, 2017
Primary completionActual
Mar 17, 2021
CompletionActual
Mar 17, 2021
Results first posted
May 4, 2022
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03253796
Responsible party
Sponsor
First posted
Aug 18, 2017
Start date
Nov 7, 2017
Primary completion
Mar 17, 2021
Completion
Mar 17, 2021
Results posted
May 4, 2022
Last update
Jul 28, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golimumab

Start the discussion